Melanocortin-4 Receptor Agonists for Obesity and Diabetes Treatment
Summary
The USPTO published patent application US20260092056A1 for melanocortin-4 receptor agonists developed by eight inventors. The compounds of Formula 1 demonstrate agonist activity against melanocortin-4 receptors and may be useful in preventing or treating obesity, diabetes, inflammation, and erectile dysfunction.
What changed
The USPTO published a patent application for melanocortin-4 receptor agonists classified under CPC C07D 413/14. The application covers compounds of Formula 1 exhibiting agonist activity against melanocortin-4 receptors, along with pharmaceutical compositions comprising these compounds. The claimed compounds are intended for preventing or treating obesity, diabetes, inflammation, and erectile dysfunction.
This is a routine patent application publication with no immediate compliance obligations. Pharmaceutical companies and researchers developing similar compounds should review the application to assess potential freedom-to-operate concerns or licensing opportunities. There are no deadlines, penalties, or required actions associated with this publication.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MELANOCORTIN-4 RECEPTOR AGONISTS
Application US20260092056A1 Kind: A1 Apr 02, 2026
Inventors
Seung Wan Kang, Hee Dong Park, Hee Dong Park, Su Jin Yeo, Hyun Seo Park, Ji Ho Hong, Hye Won Ahn, Eun Sil Choi
Abstract
The present invention relates to a compound exhibiting excellent agonist activity against melanocortin receptors. More specifically, the present invention relates to a compound of Formula 1, a pharmaceutical composition comprising the compound as an active ingredient, and a use thereof, and the compound of the present invention exhibits excellent agonist activity against melacortin-4 receptors and can be particularly useful in preventing or treating obesity, diabetes, inflammation and erectile dysfunction.
CPC Classifications
C07D 413/14 A61P 3/04
Filing Date
2025-12-05
Application No.
19410552
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Organic Chemistry (C07D) publishes new changes.